Fig. 2From: Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studiesTransition from FIONA to FIONA OLE study. Dagger indicates the key list of inclusion and exclusion criteria that must be fulfilled can be found in Table 1 and 2. eCRF electronic case report form, eGFR estimated glomerular filtration rate, EOT end of treatment, K + potassium, OLE open-label extension, TEAE treatment-emergent adverse eventBack to article page